2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2619

Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis
Abstract Number: 2890

Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Abstract Number: 2160

Effect of the Metabolic Syndrome on Incident Vascular Events and Mortality in Four Rheumatic Diseases: An 8-Year Longitudinal Analysis
Abstract Number: 2311

Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Abstract Number: 2524

Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
Abstract Number: 2895

Effect of Vitamin D on Serum Markers of Bone Turnover in SLE in a Randomized Controlled Trial
Abstract Number: 2004

Effective Inhibition of Metalloproteases By a Viscosupplement Based on a Hyaluronic Acid Amide (HYADD®4)
Abstract Number: 1724

Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
Abstract Number: 1740

Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Abstract Number: 347

Effectiveness of a Biopsychosocial Exercise Approach in Rheumatic Diseases
Abstract Number: 181

Effectiveness of Elective Completion in Enhancing Board Preparedness and Comfort with Diagnosing and Treating Rheumatologic Conditions in a Cohort of Internal Medicine Residents at an Academic Medical Center
Abstract Number: 2347

Effectiveness of Shared Decision Making in Systemic Lupus Erythematosus Patients at OSU
Abstract Number: 586

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort
Abstract Number: 2032

Effector T Helper Cell Differentiation and Cytokine Secretion Are Increased in Young Children with Juvenile Idiopathic Arthritis
Abstract Number: 2210

Effects of Anti-Citrullinated Peptide Antibody (ACPA) on Bone Microstructure in Rheumatoid Arthritis: A HR-pQCT Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].